Title:
ANTI-DENV3 ANTIBODIES
Document Type and Number:
WIPO Patent Application WO/2024/036265
Kind Code:
A3
Abstract:
The present invention relates to anti-dengue virus serotype 3 (DENV3) antibodies and antigen binding fragments thereof. Further, nucleic acids encoding them and host cells comprising them are provided. In addition, the use of the antibodies in the prevention or treatment of dengue disease is provided. Also, diagnostic methods using them and kits comprising them are provided.
Inventors:
DOMINGUEZ DAVID (US)
WATKINS HEATHER (US)
TSUJI ISAMU (JP)
WATKINS HEATHER (US)
TSUJI ISAMU (JP)
Application Number:
PCT/US2023/072002
Publication Date:
March 21, 2024
Filing Date:
August 10, 2023
Export Citation:
Assignee:
TAKEDA VACCINES INC (US)
International Classes:
C07K16/10
Domestic Patent References:
| WO2021154530A1 | 2021-08-05 | |||
| WO2020186687A1 | 2020-09-24 |
Foreign References:
| US20170218052A1 | 2017-08-03 | |||
| US20210017256A1 | 2021-01-21 |
Other References:
XU JOHN L ET AL: "Diversity in the CDR3 region of VH is sufficient for most antibody specificities", IMMUNITY, CELL PRESS, AMSTERDAM, NL, vol. 13, no. 1, 1 July 2000 (2000-07-01), pages 37 - 45, XP009147376, ISSN: 1074-7613, [retrieved on 20000905], DOI: 10.1016/S1074-7613(00)00006-6
YOUNG ELLEN ET AL: "Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies", CELL HOST & MICROBE, vol. 27, no. 5, 1 May 2020 (2020-05-01), NL, pages 710 - 724.e7, XP093052861, ISSN: 1931-3128, DOI: 10.1016/j.chom.2020.04.007
YOUNG ELLEN ET AL: "Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies", CELL HOST & MICROBE, vol. 27, no. 5, 1 May 2020 (2020-05-01), NL, pages 710 - 724.e7, XP093052861, ISSN: 1931-3128, DOI: 10.1016/j.chom.2020.04.007
Attorney, Agent or Firm:
FOX, Harold H. (US)
Download PDF: